TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 2 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jul 2, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Trishula Therapeutics, Inc.
- Interventions being studied
- Drug: TTX-030; Drug: Pembrolizumab; Drug: Gemcitabine; Drug: nab paclitaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Abreviated 1. Advanced solid tumor malignancy or relapsed/refractory lymphoma, or
- eligible to receive single-agent pembrolizumab as standard of care, or
- eligible to receive single-agent docetaxel as standard of care, or
- advanced pancreatic adenocarcinoma and eligible to receive gemcitabine plus nab-paclitaxel as standard of care. 2. Age 18 years or older, is willing and able to provide informed consent 3. Evidence of measurable disease 4. Life expectancy \> 12 weeks and Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Abbreviated
1. History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody. 2. Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study 3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy 4. History of severe autoimmune disease 5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UC Irvine Cancer CenterOrange, California
- UC Davis Comprehensive Cancer CenterSacramento, California
- University of California, San FranciscoSan Francisco, California
- Sylvester Comprehensive Cancer CenterMiami, Florida
- Norton Cancer InstituteLouisville, Kentucky
- Nebraska Cancer Center Oncology Hematology West P.C.Omaha, Nebraska
- Rutgers Cancer Institute of New JerseyNew Brunswick, New Jersey
- Columbia University Irving Medical CenterNew York, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Montefiore Medical CenterThe Bronx, New York
- University Hospitals Cleveland Medical CenterCleveland, Ohio
- UPMC Hillman Cancer CenterPittsburgh, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 2, 2025. Always confirm current availability with the study team.